Evrysdi – Risdiplam

Link to more information


Northwest Territories is funding EvrysdiⓇ (risdiplam) effective January 19th 2023. Criteria for funding is not public but expected to be aligned with CADTH . Criteria generally follows NIHB funding criteria given their overlap in patients.

Spinraza – Nusinersen



Initiation Criteria
1. Pre-symptomatic patients with 2 or 3 copies of the SMN2 gene,
2. Had the disease for <6 months, 2 copies of SMN2, and symptom onset after the first week after birth and on, or before seven months of age.
3. Patients under the age of 18 with symptom onset > 6 months of age, and never achieved the ability to walk independently. †

Stopping Criteria
1. For those pre-symptomatic at initiation: no improvement/maintenance on HINE-2, CHOP INTEND, or HFMSE, OR
2. For those symptomatic at initiation: no maintenance in HINE-2, CHOP INTENT, or HFMSE, OR
3. Permanent invasive ventilation required


“Funding requests for Type 2 and 3 patients 18 years of age and over, as well as Type 2 and 3 patients who have achieved the ability to walk independently will be considered on a case-by-case basis.”

Zolgensma – Onasemnogene abeparvovec


No information available at this time.